How to Vaccinate the Entire World

Manufacturing

The global vaccine distribution effort faces significant manufacturing challenges. Krishna Udayakumar highlights the dependency on different vaccine platforms, such as mRNA technology, which has not been globally scaled before 1. This results in varying manufacturing locations, with Pfizer and Moderna primarily produced in the US and Europe, while AstraZeneca's vaccine is more widely distributed, including in India and Brazil 1. He also notes the logistical hurdles, such as the need for billions of syringes and PPE, and the complexity of tracking vaccinations, especially for two-dose vaccines 2.

We should also remember that a vaccine coming off a production line is very different than a vaccination that's reached somebody's arm.

--- Krishna Udayakumar

Despite these challenges, efforts like COVAX aim to improve access in low and middle-income countries, though achieving global herd immunity remains unlikely this year 2.

   

Logistics

Logistical hurdles further complicate the global vaccine distribution. Krishna Udayakumar explains the financial and infrastructural challenges, noting that while the US has committed $4 billion to COVAX, competition for doses remains fierce 3. The Serum Institute of India, a major vaccine provider, faces pressure to meet both domestic and international demands 3. Additionally, the cost of vaccines varies widely, with AstraZeneca being the cheapest and Moderna among the most expensive 3.

Vaccines are being developed at an unprecedented rate, but we still know that getting them out to the last mile, getting to the people who need them most, is going to be just as important and just as difficult.

--- Krishna Udayakumar

The disparity in vaccine distribution is stark, with wealthy nations vaccinating rapidly while some poorer countries have yet to receive any doses 4.